科学图书馆
-
Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesWanner C, Inzucchi SE, EMPA-REG OUTCOME Investigators. -
The Year in Cardiovascular Medicine 2020: Coronary Prevention: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of coronary prevention is Professor Ramon Estruch, Dr Luis Ruilope, and Professor Francesco Cosentino. Mark Nicholls meets themM Nicholls.
-
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular DiseaseE Ajufo, CR Ayers, R Vigen et al.
-
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyPerkovic V, Jardine MJ, CREDENCE Trial Investigators.
-
Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetesCostacou T, Ferrell RE, Orchard TJ.
-
Association Between Depressive Symptoms and Incident Cardiovascular DiseasesEL Harshfield, L Pennells, Emerging Risk Factors Collaboration.
-
The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesisHI Chen , B Sharma, K Red-Horse et al.
-
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER TrialMurphy SA, Pedersen TR, Gaciong ZA et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
